Open AccessRecurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
Author(s) -
Shouki Bazarbashi,
Haya Azouz,
Amal H Abu Sabaa,
Ali Aljubran,
Ahmad Alzahrani,
Mohammed Alotaibi
Publication year - 2016
Publication title -
urology annals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.355
H-Index - 20
eISSN - 0974-7834
pISSN - 0974-7796
DOI - 10.4103/0974-7796.184891
Subject(s) - medicine , carcinoma in situ , bladder cancer , transitional cell carcinoma , population , urology , single center , univariate analysis , carcinoma , oncology , surgery , multivariate analysis , cancer , environmental health
Intravesical Bacillus Calmette-Guerin (BCG) has been the standard of care for the prevention of nonmuscle invasive bladder cancer (NMIBC) recurrence following resection. Attempts to improve on the result by combining it with other agents have largely failed. This study addresses the result of BCG therapy in our patient population and compares the result with our combination BCG and interferon therapy published earlier.